AUTOLUS THERAPEUTICS PLC's ticker is AUTL and the CUSIP is 05280R100. A total of 66 filers reported holding AUTOLUS THERAPEUTICS PLC in Q3 2022. The put-call ratio across all filers is - and the average weighting 0.5%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $247 | -94.2% | 106 | -94.1% | 0.00% | – |
Q2 2023 | $4,282 | -99.5% | 1,799 | -99.6% | 0.00% | – |
Q1 2023 | $811,000 | +86360.6% | 441,025 | -10.6% | 0.00% | – |
Q4 2022 | $938 | -99.9% | 493,509 | +11.5% | 0.00% | – |
Q3 2022 | $947,000 | -46.6% | 442,550 | -29.4% | 0.00% | – |
Q2 2022 | $1,773,000 | -46.8% | 626,519 | -21.6% | 0.00% | – |
Q1 2022 | $3,334,000 | -24.6% | 799,558 | -6.1% | 0.00% | -100.0% |
Q4 2021 | $4,419,000 | -50.1% | 851,544 | -37.0% | 0.00% | 0.0% |
Q3 2021 | $8,851,000 | +77.5% | 1,351,355 | +79.9% | 0.00% | 0.0% |
Q2 2021 | $4,986,000 | +56.9% | 750,964 | +35.5% | 0.00% | – |
Q1 2021 | $3,177,000 | +39.8% | 554,369 | +118.0% | 0.00% | – |
Q4 2020 | $2,273,000 | +6.0% | 254,260 | +42.3% | 0.00% | – |
Q3 2020 | $2,144,000 | -5.0% | 178,634 | +26.9% | 0.00% | – |
Q2 2020 | $2,256,000 | +271.1% | 140,755 | +38.7% | 0.00% | – |
Q1 2020 | $608,000 | +20.6% | 101,447 | +165.5% | 0.00% | – |
Q4 2019 | $504,000 | – | 38,213 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Syncona Portfolio Ltd | 21,346,829 | $49,738,112 | 74.10% |
TFG Asset Management GP Ltd | 12,000,000 | $27,960,000 | 5.10% |
Paradigm Biocapital Advisors LP | 14,406,782 | $33,567,802 | 2.28% |
Lynx1 Capital Management LP | 1,363,025 | $3,175,848 | 2.10% |
Deep Track Capital, LP | 15,000,000 | $34,950,000 | 1.35% |
Affinity Asset Advisors, LLC | 1,992,466 | $4,642,446 | 1.31% |
DAFNA Capital Management LLC | 928,253 | $2,162,829 | 0.67% |
Frazier Life Sciences Management, L.P. | 3,746,857 | $8,730,177 | 0.58% |
ARMISTICE CAPITAL, LLC | 6,900,000 | $16,077,000 | 0.25% |
Blackstone Inc. | 20,485,611 | $47,731,474 | 0.20% |